Tes Fibronectin Fetal Positif: Risiko, Wektu, Langkah Sabanjure

Kategori
Artikel
Kesehatan Ibu Hamil Interpretasi Lab Pembaruan 2026 Ramah Pasien

Asil positif nuwuhake pitakon bab risiko lair prematur—dudu ngetung wektu nganti lair. Asil negatif kerep luwih migunani, yen sampel lan kahanan klinis cocog karo tes kasebut.

📖 ~12 menit 📅
📝 Diterbitake: 🩺 Ditinjau kanthi medis: ✅ Adhedhasar Bukti
⚡ Ringkesan Cepet v1.0 —
  1. fFN positif lumrahé ateges fetal fibronectin wis tekan ambang tes udakara 50 ng/mL; iki ora ngonfirmasi persalinan utawa prédhiksi tanggal lair.
  2. fFN negatif bisa ndhukung anané kemungkinan cilik lair sajroning 7 dina ing pasien gejala sing dipilih kanthi trep, nanging ora bisa ngungkuli gejala sing mbutuhaké kawigatèn.
  3. Nilai prediktif gumantung marang populasi: sawijining panaliten landmark tumrap pasien kanthi gejala nglaporaké nilai prediktif positif 7 dina 12.7% lan nilai prediktif negatif 99.5%.
  4. Umur gestasi ngowahi interpretasi; akèh protokol tes kanggo pasien kanthi gejala migunakaké rentang udakara 24+0 nganti 34+6 minggu, sanajan syarat kelayakan tes béda-béda.
  5. Dawa serviks mènèhi informasi sing béda saka fFN; NICE migunakaké ambang 15 mm ing alur diagnostik kanggo pasien kanthi gejala sing umuré kandhutan 30 minggu utawa luwih.
  6. Саягӣ ҳамбистарӣ дар давоми 24 соат метавонад боэътимодии натиҷаи мусбатро коҳиш диҳад; пеш аз гирифтани намуна ё тафсири натиҷа ба гурӯҳи таваллуд хабар диҳед.
  7. Гирифтани намуна одатан бояд пеш аз муоинаи рақамии маҳбал ва дигар амалиётҳое анҷом дода шавад, ки метавонанд намунаро тағйир диҳанд; дастурҳои санҷишро риоя кунед.
  8. Penilaian sing mendesak ҳангоми ихроҷи моеъ, хунравӣ, кашишҳои мунтазами дарднок ё кам шудани ҳаракати ҷанин зарур аст—ҳатто баъди натиҷаи манфӣ.
  9. Keputusan perawatan аз эҳтимолияти умумӣ ва вақти таваллуд вобастаанд; танҳо натиҷаи мусбати fFN худ аз худ маънои зарурати истифодаи стероидҳо, бистарӣ шудан ё истироҳати мутлақро надорад.

Apa sejatine tegesé asil fetal fibronectin positif?

A натиҷаи мусбати санҷиши фибронектини ҷанин маънои онро дорад, ки тампон сафедаи марбут ба интерфейси бофтаҳои ҳомиладориро ошкор кардааст, одатан дар ҳудуди тақрибан 50 ng/mL ё бештар. Ин нигарониро дар бораи хатари таваллуди пеш аз муҳлат зиёд мекунад, аммо оғози зоишро тасдиқ намекунад ва маънои онро надорад, ки кӯдаки шумо дар давоми чанд рӯз ба дунё меояд.

Fetal fibronectin protein and extracellular matrix illustrated beside a pregnancy swab assay
Gambar 1: Фибронектини ҷанин тағйироти интерфейси бофтаҳоро нишон медиҳад, на санаи тасдиқшудаи таваллудро.

Фибронектини ҷанин, ки кӯтоҳ fFN номида мешавад, гликопротеини матрикси берунҳуҷайравӣ буда, дар интерфейси байни пардаҳои ҳомиладорӣ ва бофтаи модар ҷойгир аст. Муайян шудани ин сафеда дар миёнаи ҳомиладорӣ метавонад бо халалдоршавии он интерфейс ҳамроҳ бошад, аммо натиҷаи аз 50 ng/mL зиёд кушодашавии гарданаки бачадон, кашишҳо ё омодагии кӯдакро ба таваллуд чен намекунад.

Бемори фарзиро дар ҳафтаи 29-уми ҳомиладорӣ тасаввур кунед, ки метавонад ҳисси сахтшавии шикам, натиҷаи мусбати тампон, пардаҳои солим ва ҳангоми мушоҳида тағйир наёфтани гарданаки бачадон дошта бошад; бемори дигар бо ҳамон натиҷа метавонад васеъшавии афзояндаи гарданаки бачадон дошта бошад. Инҳо ҳолатҳои клиникии гуногунанд ва аз ҳамин сабаб ман натиҷаро ҳамчун нишонаи хатар, на ташхис, шарҳ медодам.

Kantesti iku sawijining Analisa tes getih AI, дар ҳоле ки фибронектини ҷанин одатан аз намунаи тампони маҳбал чен карда мешавад, на аз намунаи хун. Ман Томас Клейн, MD, сардухтури тиббии Kantesti ҳастам; ин фарқ муҳим аст, зеро ҳадди 50 ng/mL барои тампони акушерӣ истифода мешавад, на барои таҳлили муқаррарии лабораторӣ, чунон ки дар latar mburi organisasi nerangake.

Cara kerja swab fFN—lan tegesé 50 ng/mL

Ing санҷиши фибронектини ҷанин дида мешавад, ки намунаи маҳбалро ҳангоми муоина бо оинаи тиббӣ мегирад; ҳадди маъмули сифатӣ 50 ng/mL. Ин ҳадд категорияҳои санҷишро ҷудо мекунад, на ҳомиладории бехатарро аз ҳомиладории ҳатман бо таваллуди пеш аз муҳлат анҷомёбанда.

Fetal fibronectin collection swab, extraction container, and rapid immunoassay cartridge
Gambar 2: Санҷиши тампон сафедаро чен мекунад, на ташхиси кашишҳоро.

fFN-и сифатӣ натиҷаи мусбат ё манфиро нишон медиҳад, дар ҳоле ки санҷиши миқдорӣ консентратсияро нишон медиҳад ва баъзан гурӯҳҳои хатар, аз қабили 10, 50, 200 ва 500 ng/mL-ро истифода мебарад. Мо pandhuan kualitatif vs kuantitatif фарқи тарзи пешниҳоди натиҷаҳоро шарҳ медиҳем, ҳарчанд намунаҳои он санҷишҳои хунанд, на тампонҳои акушерӣ.

Консентратсияи fFN баробари 55 ng/mL and one of 500 ng/mL can both appear as positive on a binary report, even though a quantitative pathway may assign different risk estimates. Ask whether the original report contains an actual concentration; the word positive may conceal information that the laboratory measured but the discharge summary omitted.

Boundary values need assay-specific reading: many qualitative assays classify 50 ng/mL or above as positive, whereas NICE describes 50 ng/mL or less as negative and more than 50 ng/mL as positive in its numerical pathway. NICE NG25 and the laboratory's reporting convention should therefore be read together rather than treating exactly 50 as universally classified.

Common qualitative negative category <50 ng/mL Supports a lower short-term delivery probability when the patient and sample meet assay eligibility.
Common qualitative positive category ≥50 ng/mL Raises risk concern but does not diagnose labor or establish imminent delivery.
NICE numerical boundary ≤50 versus >50 ng/mL NICE NG25 uses this numerical distinction when fFN is used in its specified diagnostic pathway.
Higher quantitative concentrations Examples: 200 or 500 ng/mL May increase estimated risk in validated quantitative models; there is no universal concentration that makes birth certain.

Napa akèh asil fFN positif ora prédhiksi lair sajroning seminggu

A positive fFN test has limited ability to predict delivery within 7 dina, because many symptomatic patients do not deliver during that period. In Peaceman et al.’s multicenter study, the 7-day positive predictive value was 12.7%.

Physical obstetric assessment sequence showing swab testing followed by clinical observation
Gambar 3: A positive swab is one step in a wider assessment.

Nilai prediktif positif describes how many patients with a positive result experience the outcome being predicted; it is not the percentage of all pregnancies that deliver prematurely. In Peaceman et al. (1997), approximately 13 of every 100 positive patients delivered within 7 days, so most positives did not indicate delivery that week.

Ing starting probability changes the meaning of the same positive swab: a patient with previous spontaneous birth at 28 weeks, increasing contractions, and cervical change is not equivalent to someone with mild intermittent tightening and a closed cervix. The 12.7% study estimate is useful for explaining uncertainty, but I would not present it as either patient's personalized probability.

Positive does not always mean disease, and the interpretation depends on what the test detects: protein, antibody, genetic material, or another target. Our pregnancy antibody-screen explanation addresses a different pregnancy test; neither an antibody result nor fFN above 50 ng/mL can be interpreted solely from the word positive.

Apa sing bisa—lan ora bisa—diandharaké déning tes fetal fibronectin negatif

A fetal fibronectin test negative result can help identify a low probability of birth within 7 dina in appropriately selected symptomatic patients. Peaceman et al. reported a 7-day negative predictive value of 99.5%, but that figure is not a lifetime guarantee for the pregnancy.

Pregnant patient reviewing a blank appointment card beside an obstetric swab transport kit
Gambar 4: A reassuring result applies to a short interval, not the entire pregnancy.

Negative predictive value is conditional on who was tested and how the sample was collected; 99.5% does not apply automatically to every gestational age or complication. The landmark estimate came from a defined symptomatic population, so clinicians should not simply transfer it to ruptured membranes, advanced dilation, or a completely different testing indication.

A negative fFN result today may support discharge after a reassuring examination, but symptoms that restart 3 days later deserve a fresh assessment. The original swab did not examine tomorrow's cervix or predict a later membrane rupture; the discharge plan should explain which changes require a return rather than saying only that the test was normal.

Pregnancy alters laboratory interpretation in more than one way, including kidney-function results and the eligibility of obstetric prediction tests. Our pregnancy kidney-function guide illustrates why gestation-specific context matters; a negative fFN below 50 ng/mL still needs its own obstetric examination and safety instructions.

Napa umur gestasi ngowahi tegesé asil fFN

Umur gestasi determines whether fFN testing is appropriate and what decisions its result can support. Many symptomatic protocols use approximately 24+0 to 34+6 weeks, but eligibility varies by assay and local maternity pathway.

Standing pregnant patient and clinician discussing gestational timing beside a swab collection kit
Gambar 5: Gestational timing determines both test eligibility and the consequences of uncertainty.

Fetal fibronectin can be present physiologically earlier in pregnancy and closer to term, which limits interpretation outside the intended testing window. A positive result at 18 weeks should not be assigned the same 7-day predictive value as a correctly collected sample at 29 weeks; the assay's validated population is part of the result.

Before 30 weeks, NICE NG25 recommends treating clinically suspected preterm labor rather than relying on its later-gestation testing pathway to exclude it. At 30 weeks or later, the guideline offers cervical-length assessment and, when that is unavailable or unacceptable, fFN; the difference reflects the consequences of missing a very early birth, not a sudden biological change on one birthday.

A normal test cannot overrule an urgent presentation, especially when the test was used outside its intended population. Our normal-results and acute-pain guide explains this diagnostic principle in another setting; an fFN result below 50 ng/mL likewise cannot substitute for examination when pregnancy symptoms are concerning.

Cara dawa serviks ngowahi interpretasi fFN positif

Transvaginal cervical length measures an anatomical feature that fFN does not: how much closed cervix remains. For symptomatic patients at 30 weeks or later, NICE uses 15 mm in its diagnostic pathway, while other protocols use different thresholds and combinations.

Watercolor illustration of obstetric ultrasound equipment used for cervical-length assessment
Gambar 6: Ultrasound supplies anatomical information that a protein swab cannot provide.

A 35 mm cervix and a 12 mm cervix should not be treated as interchangeable findings merely because both patients have positive swabs. The shorter measurement usually increases concern, particularly with symptoms or cervical change; however, interpretation also depends on gestational age, measurement quality, and whether the clinician is diagnosing labor or estimating future risk.

NICE NG25 does not recommend combining cervical length and fFN to diagnose preterm labor in its specified pathway. Some services use combined risk assessment, particularly in intermediate cervical-length groups, but that is a different protocol; ask which pathway your unit follows rather than assuming a positive swab always cancels a reassuring measurement above 15 mm.

The 25 mm threshold often discussed in pregnancy relates to short-cervix screening and preventive decisions in particular earlier-gestation populations, not a universal diagnosis of symptomatic labor. Our progesterone reference guide explains another pregnancy measurement; do not start, stop, or increase progesterone because an fFN swab exceeds 50 ng/mL.

Gejala endi sing luwih wigati tinimbang asil swab?

Progressive cervical change, suspected membrane rupture, bleeding, and concerning maternal or fetal findings can outweigh a reassuring fFN result. A negative swab below 50 ng/mL does not make regular painful contractions or fluid leakage safe to manage without assessment.

Paired obstetric assessment layouts with swab kits and ultrasound equipment for clinical comparison
Gambar 7: Similar swab results can accompany very different examination findings.

Contractions alone do not establish preterm labor, because tightening can occur without progressive cervical dilation; the assessment looks for the combination of symptoms and change. At 31 weeks, a patient whose contractions settle and whose examination remains unchanged differs from one whose cervix opens during observation, even if both swabs read positive.

Wong hipotetis 28-week pregnancy with fluid leakage illustrates the test's limit: the first question is whether membranes have ruptured, not whether an fFN concentration is below 50 ng/mL. When membrane rupture is suspected, clinicians use the appropriate history, examination, and testing pathway; an fFN result should not be repurposed as a membrane-rupture exclusion test.

Kantesti iku sawijining platform interpretasi hasil tes getih AI, and an fFN swab at 50 ng/mL belongs to a clinical pathway our routine blood-analysis output cannot replace. Our kerangka validasi klinis explains why a measured laboratory value and a validated obstetric triage decision are separate questions.

Apa sing njalari asil fetal fibronectin positif palsu?

A fetal fibronectin false positive can reflect collection interference or protein detected without delivery during the predicted interval. Recent intercourse within 24 jam, bleeding, and examination-related disturbance can make a positive result less straightforward to interpret.

Educational microscopic-style view of a swab tip and protein-containing sample material
Gambar 8: Sample conditions influence whether a positive assay reflects useful risk information.

Analytical false positivity and prediction failure are different problems: an assay may genuinely detect fFN above 50 ng/mL while the patient does not deliver within 7 days. Calling every non-delivery a laboratory error misses the biology—the interface may have changed without progressing to labor, or the predicted outcome may simply not have occurred in that interval.

Collection order matters, so the swab is generally obtained before a digital vaginal examination and before other procedures that could affect the sample, following assay instructions. If an examination happened 20 minutes earlier, tell the team; that information may change confidence in a positive result without automatically proving that it is false.

Specimen quality belongs in the interpretation, not in a footnote added after treatment decisions. Our sample-interference explanation describes a different laboratory problem; fFN above 50 ng/mL has its own interference rules, and blood-sample advice should not be transferred directly to a vaginal swab.

Pengaruh hubungan seksual anyar-anyar iki lan produk vaginal marang fFN

Intercourse within the previous 24 hours can reduce confidence in a positive fFN result, so disclose it before sampling. Vaginal products and recent procedures may also matter, but the laboratory's assay instructions determine whether collection should be delayed or the result qualified.

Fetal fibronectin antibody-binding illustration showing the importance of sample conditions
Gambar 9: Assay instructions help separate detectable protein from collection-related interference.

A positive result after recent intercourse is not automatically evidence of imminent birth; the maternity team may regard that sample as unsuitable for confident positive interpretation. Some assay instructions allow a negative result to retain clinical usefulness despite intercourse within 24 hours, but this is not a blanket rule across every product and testing pathway.

Vaginal medication should not be stopped independently to obtain a cleaner swab, including prescribed progesterone used during pregnancy. Tell the clinician what was used and when—for example, a dose 8 hours before collection—so the unit can check its instructions; a delay in testing must never become a delay in assessing painful contractions or fluid leakage.

fFN is not an STI test, and positive fFN above 50 ng/mL does not diagnose chlamydia or another infection. Our chlamydia sampling and timing guide explains a separate assay, while bakteri tanpa gejala urin addresses another pregnancy-relevant question that requires its own specimen and treatment criteria.

Kapan sampeyan kudu langsung ngubungi layanan triase maternitas?

Contact maternity triage promptly for regular painful contractions before 37 weeks, fluid leakage, vaginal bleeding, or reduced fetal movement. Seek assessment even if yesterday's fFN result was negative; a reassuring short-term prediction does not exclude a new complication.

Pregnant patient approaching modern maternity triage with a swab kit visible at the assessment station
Gambar 10: New warning symptoms require assessment regardless of the previous swab result.

Do not wait for a contraction-count target if you suspect your waters have broken or your baby's movements have changed. A person at 30 weeks with repeated watery leakage needs maternity advice even without strong contractions; fFN testing is not a home decision tool, and a previous negative result should not postpone contact.

Severe headache, visual disturbance, upper abdominal pain, or sudden illness also deserve urgent pregnancy assessment because they may indicate conditions unrelated to fFN. Our HELLP warning-pattern guide explains one such emergency; a swab below 50 ng/mL offers no reassurance about blood pressure, platelets, or liver injury.

Different pregnancy symptoms need different tests: persistent itching, especially on palms or soles, may prompt bile-acid testing rather than another fFN swab. Our pregnancy bile-acid guide explains that distinction; tell triage your gestational age, the symptom onset time, and whether movement has changed in the past 24 hours.

Apa asil fFN positif ateges kudu diwènèhi steroid utawa dirawat ing rumah sakit?

A positive fFN result alone does not automatically require admission, corticosteroids, or medication to suppress contractions. Clinicians consider whether birth is genuinely likely within approximately 7 dina, the gestational age, cervical findings, membrane status, and access to appropriate neonatal care.

Brand-neutral obstetric ultrasound instrument beside a fetal fibronectin assay kit
Gambar 11: Treatment decisions combine gestational timing, imaging, symptoms, and swab findings.

Antenatal corticosteroids help fetal maturation when early birth is sufficiently likely; they are not a treatment for fFN protein itself. NICE offers them at 24+0 to 33+6 weeks for relevant suspected or established preterm-birth situations and considers them at 34+0 to 35+6 weeks, with individualized discussion at earlier gestations; a positive swab must be interpreted within that clinical decision.

Tocolysis may buy time, commonly around 48 hours, for steroids or transfer when delaying birth is appropriate; it does not guarantee continuation to term. Magnesium sulfate for fetal neuroprotection has separate gestational and imminent-birth criteria, and antibiotics are not routinely indicated solely because fFN exceeds 50 ng/mL with intact membranes and no diagnosed infection.

Routine testing has not clearly improved every outcome, even though negative results can help risk assessment: Berghella and Saccone's Cochrane review (2019) found limited trial evidence for management guided by fFN results. I would therefore ask what decision the test changes in the next 24–48 hours; our medical-report safety checklist supports that distinction between interpreting a result and prescribing care.

Peran tes getih lan cipratan bebarengan karo swab fFN

Blood and urine tests investigate different concerns from fFN, such as anemia, urinary infection, or maternal illness. A hemoglobin result in g/dL, a ferritin result in ng/mL, and an fFN swab concentration cannot be treated as interchangeable indicators of preterm labor.

Separate fetal fibronectin swab assembly and laboratory tube illustrating different specimen types
Gambar 12: Different specimen types answer different questions during a pregnancy assessment.

Low iron stores do not explain away contractions, and a reassuring complete blood count does not exclude preterm labor. If ferritin is 12 ng/mL in a patient at 28 weeks, the clinician may address iron depletion while still assessing the contractions separately; our pregnancy ferritin guide explains the iron question rather than fFN risk.

Pregnancy can raise the white-cell count, so an isolated flagged count should not automatically be labeled infection or used to explain a positive fFN. Our pregnancy neutrophil reference guide discusses that context; the clinician still considers temperature, urinary symptoms, examination, and cultures, rather than using one count or a 50 ng/mL swab threshold as a diagnosis.

Iron-panel interpretation involves several related measurements, including ferritin and transferrin saturation, but none replaces cervical assessment. Our iron-studies interpretation guide explains those relationships; when reviewing a 3-part pregnancy workup—swab, blood panel, and urine specimen—keep each test linked to the question it was ordered to answer.

Apa sing kudu ditakokaké sadurungé mulih sawisé tes fFN?

Before discharge, ask what your fFN result changes, whether the sample was valid, and which symptoms require immediate return. A plan should specify the short-term assessment interval—often framed around 7 dina—without implying that a negative result guarantees the rest of pregnancy.

Physical fFN follow-up pathway with swab kit, ultrasound probe, and blank appointment card
Gambar 13: A useful discharge plan connects the result to clear return instructions.

Five practical questions are worth asking: What is my exact gestational age? Was my cervix measured or examined? Were my membranes intact? Could intercourse or a procedure affect the swab? What symptoms mean I should return immediately? A positive result above 50 ng/mL is much easier to understand when those answers are recorded alongside it.

Retesting is not a universal countdown schedule, and a second swab is useful only if it fits a validated pathway and can change management. If tightening restarts 4 days after a reassuring assessment, contact maternity triage rather than independently arranging another fFN test; examination, membrane assessment, or observation may be more useful than repeating the original measurement.

Kantesti iku sawijining Piranti analisis tes getih berbasis AI, not a substitute for examining a pregnant patient with new symptoms or interpreting a swab above 50 ng/mL in isolation. Our standar konten medis describe the boundary between educational explanation and individualized care; routine bed rest is not automatically justified by a positive fFN and can introduce its own harms.

Bukti, tinjauan klinis, lan publikasi panaliten

fFN interpretation rests on obstetric evidence, particularly the population tested, the prediction interval, and the clinical pathway. As of 21 Oktober 2026, this article distinguishes NICE NG25 recommendations from the 1997 predictive study and the 2019 Cochrane review rather than inventing a new universal cutoff.

Fetal fibronectin rapid assay and protein model arranged for evidence-focused medical education
Gambar 14: Obstetric evidence supports risk interpretation, not certainty from one protein result.

Prediction and better outcomes are separate claims: Peaceman et al. reported 7-day predictive values, while Berghella and Saccone evaluated whether knowing fFN results improved management outcomes. NICE NG25 supplies a clinical pathway, not a promise that every positive above 50 ng/mL requires identical treatment; these sources should not be collapsed into one accuracy percentage.

Medical review should examine the whole decision, including gestation, symptoms, cervical findings, and sample validity—not just the 50 ng/mL threshold. My editorial emphasis as Thomas Klein, MD, is that understandable uncertainty is safer than false certainty; our dewan penasehat medis describes the expertise behind medical oversight, without this draft asserting a named individual's completed review.

The 2 supplied Kantesti repository publications concern blood-test interpretation and hematology, not prospective validation of fFN prediction or treatment decisions. They are listed below as research resources with DOI links and publication-search links; our sumber daya interpretasi RDW covers red-cell measurements, which cannot establish the meaning of an obstetric swab or predict delivery within 7 days.

Pitakonan sing Sering Ditakoni

Apa asil tes fetal fibronectin sing positif tegese aku bakal nglairake luwih awal?

Asil tes fetal fibronectin ora mesthekake yen sampeyan bakal nglairake prematur utawa sajrone 7 dina sabanjure. Biasane iki tegese swab ndeteksi fFN ing ambang positif tes kasebut, lumrahe udakara 50 ng/mL. Ing studi penting marang pasien sing ngalami gejala, nilai prediktif positif kanggo 7 dina yaiku 12.7%, mula umume pasien kanthi asil positif ora nglairake ing minggu kasebut. Umur gestasi, gejala, temuan serviks, status membran, lan validitas sampel sampeyan nemtokake apa sing bakal ditindakake sabanjure.

Sepira nglegakake asil tes fibronectin janin sing negatif?

Asil tes fetal fibronectin negatif bisa ndhukung kemungkinan cilik bakal nglairake sajrone 7 dina tumrap pasien sing ngalami gejala lan dipilih kanthi trep. Peaceman et al. nglaporake nilai prediktif negatif 7 dina sebesar 99.5%, nanging perkiraan kasebut khusus kanggo populasi lan kahanan ing panliten kasebut. Asil negatif ora njamin persalinan bakal kelakon nalika cukup wulan utawa ngilangi kemungkinan komplikasi anyar. Hubungi triase maternitas yen ana cairan anyar sing metu, getihen, kontraksi nyeri sing teratur, utawa gerakan janin suda, preduli saka asil sadurunge.

Apa hubungan seksual bisa njalari asil tes fFN positif palsu?

0: Sesambungan seksual sajrone 24 jam sadurunge bisa ndadekake asil tes fibronectin janin sing positif kurang bisa dipercaya. Kandhanana tim maternitas sadurunge swab dijupuk, utawa sawisé kuwi yen sampeyan lagi éling yèn wektu sesambungan bisa ana pengaruhé. Sawetara pandhuan tes ngidinaké asil négatif tetep migunani ing kahanan iki, nanging gumantung marang tes lan alur penanganan tartamtu. Aja nundha pemeriksaan darurat kanggo gejala meteng mung kanggo ngentèni nganti wektu jeda tes kliwat.

Apa tegesé asil tes fFN positif kanthi dawa cervix normal?

Asil tes fFN sing positif kanthi dawa serviks sing nyenengake bisa uga nuduhake tingkat kakuwatiran sing luwih sithik tinimbang asil swab sing padha nalika serviks cendhak banget, nanging interpretasine gumantung marang protokol. Pangukuran 35 mm lan pangukuran 12 mm menehi informasi anatomi sing beda. NICE nggunakake ambang 15 mm ing jalur kanggo pasien sing duwe gejala nalika umur kandhutan 30 minggu utawa luwih lan ora nyaranake nggabungake dawa serviks lan fFN kanggo diagnosa persalinan preterm ing jalur kasebut. Layanan liyane bisa uga nggunakake model risiko gabungan, mula takona protokol endi sing dadi pandhuan perawatanmu.

Apa asil tes fFN sing positif ateges aku kudu injeksi steroid?

0. Asil tes fFN dhewe ora kanthi otomatis ateges sampeyan kudu nampa kortikosteroid antenatal. Klinisi bakal netepake apa kemungkinan lair prematur cukup gedhe sajrone kira-kira 7 dina lan apa perawatan cocog karo umur gestasi lan kahanan sampeyan. NICE nawakake kortikosteroid ing umur gestasi 24+0 nganti 33+6 minggu kanggo kahanan tartamtu nalika dicurigai utawa wis kedadeyan lair prematur, lan nimbang menehi kortikosteroid ing umur gestasi 34+0 nganti 35+6 minggu. Owah-owahan serviks, kahanan membran, temuan liyane, lan perawatan sadurunge kabeh penting.

Apa fibronectin janin kuwi tes getih, lan apa bisa digunakake sawisé banyu ketuban saya pecah?

Fibronectin janin biasane diukur saka usapan vagina, dudu spesimen getih. Akèh tes kanggo pasien sing nuduhaké gejala ditujokake kanggo pasien kanthi membran sing isih utuh ing rentang umur gestasi tartamtu, asring kira-kira 24+0 nganti 34+6 minggu. Yen banyu ketuban sampeyan bisa uga wis pecah, hubungi layanan triase maternitas kanggo penilaian pecah membran sing trep, aja mung ngandelake asil fFN. Asil usapan negatif ing sangisoré 50 ng/mL ora bisa kanthi aman nyingkirake kemungkinan pecah membran.

Entuk Analisis Tes Getih Berbasis AI Dina Iki

Gabung karo luwih saka 2 yuta pangguna ing saindenging jagad sing percaya Kantesti kanggo analisis tes lab sing instan lan akurat. Unggah asil tes getihmu lan tampa interpretasi lengkap saka 15,000+ biomarker sajrone sawetara detik.

📚 Publikasi Riset sing Dirujuk

1

Klein, T., Mitchell, S., & Weber, H. (2026). Penganalisis Tes Getih AI: 2.5M Tes Dianalisis | Laporan Kesehatan Global 2026. Riset Medis AI Kantesti.

2

Klein, T., Mitchell, S., & Weber, H. (2026). Tes Getih RDW: Pandhuan Lengkap kanggo RDW-CV, MCV & MCHC. Riset Medis AI Kantesti.

📖 Referensi Medis Eksternal

3

National Institute for Health and Care Excellence (2015; updated 2022). Preterm labour and birth: NICE guideline NG25. NICE.

4

Peaceman AM et al. (1997). Fetal fibronectin as a predictor of preterm birth in patients with symptoms: a multicenter trial. American Journal of Obstetrics and Gynecology.

5

Berghella V, Saccone G (2019). Fetal fibronectin testing for reducing the risk of preterm birth. Cochrane Database of Systematic Reviews.

2M+Tes Analisa
127+negara-negara
75+Basa

⚕️ Penafian Medis

Sinyal Kepercayaan E-E-A-T

⭐

Pengalaman

Tinjauan klinis sing dipimpin dokter babagan alur kerja interpretasi lab.

📋

Keahlian

Fokus kedokteran laboratorium babagan carane biomarker tumindak ing konteks klinis.

👤

Kewibawaan

Ditulis dening Dr. Thomas Klein kanthi ditinjau dening Dr. Sarah Mitchell lan Prof. Dr. Hans Weber.

🛡️

Kapercayan

Interpretasi adhedhasar bukti kanthi tindak lanjut sing cetha kanggo nyuda rasa kaget.

🏢 Kantesti LTD Didaftar ing Inggris & Wales · Nomer Perusahaan. 17090423 London, Inggris Raya · kantesti.net
blank
Miturut Prof. Dr. Thomas Klein

Dr. Thomas Klein minangka ahli hematologi klinis sing wis tersertifikasi dewan, dadi Chief Medical Officer ing Kantesti AI. Kanthi pengalaman luwih saka 15 taun ing bidang kedokteran laboratorium lan nduwèni minat gedhé marang interpretasi asil tes getih sing didhukung AI, dhèwèké ngupaya nyambungake teknologi anyar karo praktik klinis saben dina. Bidang sing dadi minaté kalebu analisis biomarker, riset clinical decision support, lan optimalisasi rentang rujukan sing spesifik kanggo populasi. Minangka CMO, dhèwèké nyumbang masukan klinis kanggo benchmarking internal platform lan menehi pengawasan klinis kanggo mutu medis saka laporan pendhidhikan Kantesti.

Maringi Balesan

Alamat email Sampéyan ora dijedulne utāwā dikatonke. Ros sing kudu diisi ānā tandané *